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Hepatic stem cells with self-renewal and
liver repopulation potential are harbored in
CDCP1-positive subpopulations of human
fetal liver cells
Ran-Ran Zhang1,6†, Yun-Wen Zheng1,2,3*† , Bin Li4†, Yun-Zhong Nie1, Yasuharu Ueno1, Tomonori Tsuchida1
and Hideki Taniguchi1,5*
Abstract
Background: Mature human hepatocytes are critical in preclinical research and therapy for liver disease, but are
difficult to manipulate and expand in vitro. Hepatic stem cells (HpSCs) may be an alternative source of functional
hepatocytes for cell therapy and disease modeling. Since these cells play an import role in regenerative medicine,
the precise characterization that determines specific markers used to isolate these cells as well as whether they
contribute to liver regeneration still remain to be shown.
Method: In this study, human HpSCs were isolated from human primary fetal liver cells (FLCs) by flow cytometry
using CDCP1, CD90, and CD66 antibodies. The isolated CDCP1+CD90+CD66– HpSCs were cultured on dishes coated
with type IV collagen in DMEM nutrient mixture F-12 Ham supplemented with FBS, human γ-insulin, nicotinamide,
dexamethasone, and L-glutamine for at least 2 weeks, and were characterized by transcriptomic profiling,
quantitative real-time PCR, immunocytochemistry, and in-vivo transplantation.
Results: The purified CDCP1+CD90+CD66– subpopulation exhibited clonal expansion and self-renewal capability, and
bipotential capacity was further identified in single cell-derived colonies containing distinct hepatocytes and
cholangiocytes. Moreover, in-vivo liver repopulation assays demonstrated that human CDCP1+CD90+CD66– HpSCs
repopulated over 90% of the mouse liver and differentiated into functional hepatocytes with drug metabolism activity.
Conclusions: We identified a human hepatic stem/progenitor population in the CDCP1+CD90+CD66– subpopulation
in human FLCs, indicating CDCP1 marker could potentially be utilized to identify and isolate HpSCs for further
cytotherapy of liver disease.
Keywords: Hepatic stem cells, Transplantation, Drug metabolism
Background
Liver organ transplants are the only available and efficient
treatment for patients with end-stage liver failure; however,
there is an increasing shortage of liver donors [1, 2]. Hep-
atocyte transplantation has become a viable alternative
rescue [3, 4]. However, adult hepatocytes show minimal
proliferative activity in vivo, which is consistent with the ab-
sence of hepatocellular proliferation in the normal liver,
and are difficult to cryopreserve [5, 6]. Therefore, human
adult hepatocytes have limited applications in physiopathol-
ogy [7, 8], pharmacology [9], and toxicology [10], and the
development of new alternative sources of human hepato-
cytes is essential. Hepatocyte-like cells (iHeps) can be de-
rived from fibroblasts by direct reprogramming [11, 12] or
from human induced pluripotent stem cells (iPSCs) [13] by
differentiation; however, incomplete conversion causes im-
paired hepatocyte function [14] and incomplete iPSC repro-
gramming leads to carcinogenesis in vivo, thereby limiting
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clinical applications of these cell types [15]. Human hepatic
stem cells (HpSCs) from the liver lineage have therefore be-
come an attractive alternative cell source to primary
hepatocytes.
HpSCs separated from fetal and postnatal livers could
give rise to differentiated hepatocytes in vitro and more
mature hepatocytes in vivo, providing an opportunity to
overcome the obstacles already described [16, 17]. Indeed,
many researchers have isolated, purified, and character-
ized HpSCs from human and rodent livers using flow cy-
tometry. HpSCs have been shown to express CD29,
CD49f [18], CD13 [19], CD117, CD133, EpCAM [20], and
DLK [21], as well as markers of both hepatocyte and cho-
langiocyte lineages (such as albumin (ALB), alpha-
fetoprotein (AFP), cytokeratin 18 (CK18), and CK19 [22])
and, more importantly, markers of both hematopoietic
and mesenchymal stem cells (i.e., CD34, CD45, CD90, and
CD109) [16, 23]. Notably, HpSCs that express a broad
spectrum of markers have been identified previously; how-
ever, the specific marker expression profile that can be
used to identify and isolate HpSCs from human primary
fetal liver cells (FLCs) is still unclear.
CD90 (Thy-1), which was first reported in hematopoietic
[24] and mesenchymal [25] stem cells, has also been identi-
fied as an oval cell marker [26] and is expressed in hepatic
cancer stem cells of human liver cancer [27] as well as in
hepatic stem/progenitor cells during liver development, but
is rarely detected in adult liver cells [22, 28]. However, only
CD90 is insufficiently sensitive or specific to be a marker
for human HpSC isolation.
CUB domain-containing protein 1 (CDCP1) may be in-
volved in cell adhesion or extracellular matrix interaction,
and the expression of CDCP1 has been shown to correlate
with the metastasis of carcinoma cells, such as in cancers
of the colon [29], lung [30], breast [31], and pancreas [32].
In addition, numerous studies have shown that CDCP1
could also phenotypically identify hematopoietic stem cells
[33–35] and mesenchymal and neural stem cells [34].
However, no studies have investigated the role of CDCP1
on HpSC isolation from human primary FLCs.
In the present study, we sought to isolate and
characterize human HpSCs to determine their capacity
for self-renewal and liver repopulation. Our data support
that CDCP1 is a novel critical HpSC marker in combin-
ation with CD90 and CD66 expression.
Results
CDCP1 is a candidate marker for isolating clonal HpSCs
from human primary FLCs
First, we confirmed whether human primary FLCs exhib-
ited HpSC features. Under the clonal colony-forming assay,
human primary FLCs grew in cell colonies with densities as
low as 100 cells/cm2 on collagen IV-coated plates (Add-
itional file 1: Figure S1A). Furthermore, cells coexpressing
ALB and CK19 or AFP and CK19 were found in human
primary FLCs, demonstrating the potential to give rise to
hepatocytes and cholangiocytes (Additional file 1: Figure
S1B). Our previous finding showed that mouse HpSCs were
enriched in CD29highCD49f+/low mouse primary FLCs (c-
Kit–CD45–Ter119– cells) [36], and in human primary FLCs
the CD29highCD49f+/low fraction exhibited a profile similar
to that in mouse primary FLCs (Additional file 1: Figure
S1C), further confirming that HpSCs might exist in human
primary FLCs. To identify specific cell surface markers cor-
related with HpSC isolation, we utilized antigenic expres-
sion profiling by flow cytometry of hepatic and/or stem
cell-related markers reported previously. These data re-
vealed that human primary FLCs were highly enriched in
CD29 (98.7%), CD49f (89.8%), CD24 (84.3%), and CD44
(99.8%), but negative for CD54, CD117, CD138, CD133,
and CD140a. The oval cell marker CD90 was also
expressed in about 40.1% of human primary FLCs. Add-
itionally, we identified another candidate marker, CDCP1,
which was expressed in 18.5% of human primary FLCs,
suggesting that CDCP1 may be a novel and specific marker
of HpSC isolation (Additional file 1: Figure S1D).
Previous research has shown that CD90 is expressed in
hepatic stem/progenitor cells from adult or fetal livers [28].
Therefore, to confirm our hypothesis that CDCP1 is a spe-
cific marker of HpSC isolation, we fractionated human pri-
mary FLCs by flow cytometry using CDCP1 [34], combined
with CD90 and CD66 (Fig. 1a), yielding four subpopula-
tions of CDCP1–CD90+CD66– (24.7 ± 2.5%), CDCP1
+CD90+CD66– (8.75 ± 4.2%), CDCP1–CD90–CD66– (39.1
± 5.9%), and CDCP1+CD90–CD66– (7.68 ± 1.9%) (Fig. 1b);
here we use CD66 to remove differentiated cells [37]. Low-
density cell culture revealed that the CDCP1+CD90+CD66–
subpopulation yielded the most colonies as compared with
other three subpopulations (Fig. 1c). Moreover, a clonal cell
sorting assay (one cell per well in a 96-well plate) was per-
formed to quantify the clonogenicity efficiency according to
11 combinations of CD66, CD90, and CDCP1. The effi-
ciency of large colony formation was higher in CDCP1-
positive fractions, including CDCP1+CD90+CD66– (27.9 ±
8.6%, about 9-fold higher than the ungated subpopulation)
and CDCP1+CD90–CD66– (9.7 ± 2.0%) subpopulations,
than in CDCP1-negative fractions, including CDCP1–CD90
+CD66– (5.9 ± 1.6%) and CDCP1–CD90–CD66– (3.1 ±
1.0%) subpopulations (Fig. 1d). We continually analyzed
antigenic profiling of HpSC markers on CDCP1+CD90
+CD66– subpopulations and found that CD13, a specific
HpSC marker, was expressed in more than 80% of the
CDCP1+CD90+CD66– subpopulations. Moreover, more
than 90% of the CDCP1+CD90+CD66– subpopulations
were positive for CD24, CD49f, CD44, CD55, and CD166,
and negative for CD117, LGR5, CD45, and CD56 (Add-
itional file 2: Figure S2). In contrast, other stem cell markers
showed relatively lower positive rates: CD34 (2.4%), CD54
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(0.1%), CD138 (3.1%), CD140a (2.7%), EpCAM (6.1%), and
DLK (0.6%). Moreover, hepatitis C virus (HCV) receptors
CD81 [38] and LDLR, were also positive in CDCP1+CD90
+CD66– subpopulations (99.5% and 26.1%, respectively;
Additional file 2: Figure S2), indicating that the CDCP1
+CD90+CD66– subpopulation belongs to the hepatocyte
lineage and may have relevance to the field of virology.
From qPCR (Fig. 3a) and microarray data (Additional file 3:
Figure S3A), we noted that the target genes of the Wnt/β-
catenin signal pathway such as CAV1, PTEN, CTNNB1,
MYC, RAC1, BCL9L, GSK3A, FZD6, WNT5A, RTF1,
SNAI2, CD44, and DKK1 were enriched in CDCP1+CD90
+CD66– HpSCs, which is consistent with other studies in
which the Wnt/β-catenin pathway was shown to drive the
HpSC population [39] and liver development/regeneration
[40, 41]. When we detected cell surface marker genes (Add-
itional file 3: Figure S3B) and stem cell-related genes (Add-
itional file 3: Figure S3C) with the microarray, we found
enhanced expression of some genes, including HAS2, KDR,
PTGER2, GNB1L, FAP, IL6, SERPINE2, MET, OSMR,
CDH2, CD44, GATA2, and GATA3. These results could
provide valuable markers for comprehensively tracing and
understanding HpSCs in the developing liver.
To confirm the clonogenicity from a single putative
stem cell, cell-tracing analysis was performed. Interest-
ingly, large colonies contained more than 40,000 cells at
day 20 (Fig. 2a) and showed a typical hepatocyte morph-
ology (Fig. 2b) and strong single cell expansion potential
(Fig. 2c), indicating that CDCP1 played an important
role in colony formation and cell expansion. The cell
proliferation tracing demonstrated that the doubling
time of the cultured CDCP1+CD90+CD66– subpopula-
tion was 27.6 ± 4.7 h, consistent with a previous report
[42]. These data suggest that clonal and proliferative
HpSCs were isolated as the CDCP1+CD90+CD66– sub-
population from human primary FLCs.
CDCP1+CD90+CD66– HpSCs had bipotential and self-
renewal capabilities
To investigate whether CDCP1+CD90+CD66– HpSCs
possessed hepatic bipotential capability and cholangiocytic
differentiation ability, we evaluated single HpSC-derived
clones (one clone per well in a 96-well plate). On culture
day 14, single HpSC-derived clones were selected for gene
expression analysis (Fig. 3a). qPCR analysis showed that
all hepatic differentiation markers except for AFP, ALB,
and TAT were detected, in addition to TDO2, AAT, G6P,
CYP3A4, and CYP3A7. The cholangiocytic markers, in-
cluding CK19, CK7, GGT, and CX43, were also detected,
along with the stem cell-related markers (BMI1, c-KIT,
DLK, EPCAM, CTNNB1, c-MET, c-MYC, and PROM1).
These results indicated that each CDCP1+CD90+CD66–
HpSC has hepatic stem potential and could be differenti-
ated into hepatic and cholangiocytic lineage cells in vitro.
Additionally, after in-vitro culture of single CDCP1+CD90
+CD66– HpSC-derived clones for up to 40 days, immuno-
staining results showed that ALB-positive cells were colo-
calized with CK7 and CK19. Nearly all AFP-positive cells
coexpressed CK7. A minor subpopulation of cells
expressed both CK7 and CK19, representing more differ-
entiated cholangiocytes (Fig. 3b). These data indicate that
single HpSCs generated cell types including more mature
hepatocytes and cholangiocytes in clonal culture. The gen-
erated hepatocytes displayed functional characteristics of
mature hepatocytes, including glycogen storage and cyto-
chrome P450 protein expression (Fig. 3c). Collectively,
these results clearly showed that CDCP1+CD90+CD66–
HpSCs could differentiate into hepatocytes.
When single CDCP1+CD90+CD66– HpSC-derived col-
onies were replated in a three-dimensional (3D) gel cul-
ture system containing 1.2 mg/ml collagen I and 40%
Matrigel [43, 44], after 14 days of culture, many epithelial
cysts were formed. Some of the epithelial cysts expressed
CK7 but did not express the hepatic marker ALB (Fig. 3d).
These data suggest that our isolated HpSCs were bipoten-
tial and could give rise to hepatocytes and cholangiocytes
in vitro under suitable conditions.
5-Bromo-2-deoxyuridine (BrdU) was used to label human
primary FLCs and to detect dividing cells by flow cytometry.
The CDCP1+CD90+CD66– HpSCs exhibited higher BrdU-
positive rates (27.3%) than any other subpopulation (Fig. 4a),
suggesting enrichment of highly proliferative and self-
renewal cells. Next, we used serial sorting and single cell
clonal assays to investigate the self-renewal potential of
HpSCs in vitro. The first single cell sorting-derived HpSC
colonies were replated into new culture plates. After 14 days
of culture, the subcultured clones gradually expanded to
reach confluence and were subsequently subjected to single
(See figure on previous page.)
Fig. 1 A putative human HpSC population was identified in the CDCP1+CD90+CD66– subpopulation. a Schematic of the HpSC derivation protocol.
b Human primary FLCs costained with human antibodies against CD66, CDCP1, and CD90 for flow cytometry analysis. CD66– human primary FLCs
were reanalyzed into four fractions based on the expression of CDCP1 and CD90: CDCP1–CD90+CD66–, CDCP1+CD90+CD66–, CDCP1–CD90–CD66–,
and CDCP1+CD90–CD66–. Numbers represent the percentage of each fraction in CD66– human primary FLCs (n = 7 independent experiments). c Four
fractionated cell populations were sorted onto collagen IV-coated plates at a density of 100 cells/cm2. After 18 days of culture, colony-forming capabilities
of the cell populations were characterized by Giemsa staining. d Efficiency of large-colony formation (containing more than 100 cells per colony) derived
from clonal cell sorting as one cell per well of a 96-well plate determined from each fractionated subpopulation on day 18. Results presented as mean
colony count ± SD (n = 4 independent experiments). See also Additional file 1: Figure S1, Additional file 2: Figure S2, and Additional file 3: Figure S3. FACS
fluorescence-activated cell sorting, CDCP1 CUB domain-containing protein 1, SSC side scatter, FSC forward scatter. ***P < 0.0001
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cell sorting and culture again. After sorting four times, ex-
panded HpSCs were enriched, and FACS patterns resem-
bled the parental cell subpopulation from the second to
fourth sorting (Fig. 4b). The CFU-C efficiency was relatively
stable (Fig. 4d). Furthermore, single HpSC-derived colonies
from the first to fourth serial sorting were large and round,
with dual ALB and CK7-positive cells (Fig. 4c). More than
70% of cells in serial single cell sorting-derived HpSC col-
onies coexpressed ALB and CK7 (Table 1). The characteris-
tics described indicated that CDCP1+CD90+CD66– HpSCs
have self-renewal ability with maintained H-CFU-C effi-
ciency and ALB+CK7+ bipotential capability during serial
sorting and subculture.
To elucidate whether CDCP1 is essential for the self-
renewal of HpSCs in culture, we performed loss-of-
function assays. A single CDCP1+CD90+CD66– HpSC-
derived colony was subcultured and transfected with
CDCP1-siRNA (siCDCP1), and knockdown of the CDCP1
mRNA expression level (Fig. 5a) and CDCP1 protein level
(Fig. 5b) was observed. We tested for differences in the
proliferation rate between transfected cells and control
cells. The siCDCP1 cells grew slowly and showed growth
inhibition, with about half the cell numbers compared to
cells without CDCP1 inhibition (Fig. 5c, d). The self-
renewal capability of siCDCP1 cells was also examined
with a colony formation assay. siCDCP1 in HpSCs re-
sulted in an approximate 3-fold decrease in colony forma-
tion efficiency, and the generated colony size was
significantly smaller than the control (Fig. 5e, f ). In
addition, the migratory activity of HpSCs was suppressed
by siRNA-mediated downregulation of CDCP1 in HpSCs
(Additional file 4: Figure S4A, B). These results indicate
that CDCP1 is a key regulator of proliferation/self-renewal
and migration in HpSCs. Taken together, these data dem-
onstrate that CDCP1+CD90+CD66– HpSCs have a bipo-
tential phenotype and self-renewal capability.
Robust repopulation of liver-injured recipients with
human HpSCs
Karyotype analyses were performed on expanded HpSCs of
passage 8 and were found to be normal (Additional file 5:
Figure S5A). Then, to examine whether human HpSCs
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could expand and repopulate damaged liver tissue after
transplantation, we transplanted 106 cells into albumin
promoter-driven urokinase-type plasminogen activator
(uPA)-transgenic mice produced in severely immunodefi-
cient NOD/Shi-scid IL2Rgnull (NOG) mice (termed uPA-
NOG mice) [45]. One month after transplantation, mor-
phological and histological analyses showed that human
HpSCs were dramatically expanded in the mouse liver
(Fig. 6a, b, Additional file 5: Figure S5B).
To determine whether human HpSCs matured after
transplantation, we immunohistochemically assessed for
human nuclei, human albumin (ALB), and human cytoker-
atin 19 (CK19) expression. The results showed that human
HpSC-derived human hepatocytes in mouse livers were
well differentiated with double positive for human nuclei
and human ALB (Fig. 6c, d). Human ALB-positive hepato-
cytes that were CK19-negative resembled more matured
hepatocytes, while cells that positively costained with hu-
man ALB and CK19 exhibited a bipotential capability with
differentiation into hepatocytes and cholangiocytes (Fig. 6e).
The repopulation level reached up to 90% 1 month after
transplantation (Fig. 6f). All transplanted mice livers were
assessed for human cells using an antibody against the hu-
man leukocyte antigens A, B, C (HLA) and mouse cells
using an antibody to the mouse MHC H2Kd (H2kd) anti-
gen that is specific for uPA-NOG mice. About 85% of the
cells in the liver were positive for HLA and negative for
H2Kd antigen (HLA+H2Kd–), indicating high human
HpSC cell repopulation and no cell fusion in engrafted
uPA-NOG mice (Additional file 5: Figure S5C). This sug-
gests that CDCP1+CD90+CD66– HpSCs could successfully
reconstitute the mouse liver without cell fusion and exhib-
ited a high potential for differentiation into more matured
hepatocytes in vivo.
Furthermore, on the protein level, uPA-NOG mice
transplanted with human HpSCs secreted more human al-
bumin compared with mice transplanted with human pri-
mary FLCs (Fig. 6g). Additionally, all of the four mice
transplanted with human primary FLCs died within
1 month post transplantation, while all of the seven mice
transplanted with human HpSCs survived more than
1 month. Three of them (43%) were still alive at over
60 days post transplantation (Fig. 6h), suggesting that hu-
man HpSCs were superior to human primary FLCs in
terms of repopulation efficiency, post-transplant matur-
ation, and therapeutic recovery of the damaged liver. In
addition, 2 months after human HpSC transplantation,
the ratio of 4-hydroxy-debrisoquine to debrisoquine in
human HpSC-derived humanized mouse livers was sig-
nificantly increased from 1 to 8 h after treatment with
debrisoquine, indicating that human HpSCs underwent a
maturation process and achieved certain activity in vivo
(Fig. 6i). Since human primary FLC derived-humanized
mice died within 1 month post transplantation, we could
not perform debrisoquine metabolic assays. All of the data
demonstrated that transplanted human HpSCs could effi-
ciently repopulate recipient mouse livers and had the po-
tential to differentiate into functional hepatocytes with
drug metabolism activity in uPA-NOG mice.
Discussion
Because hepatocyte transplantation for the treatment of
liver diseases is considered a viable alternative to organ
transplantation due to the severe shortage of donor livers,
researchers have been attempting to identify appropriate
hepatocyte candidates for clinical and pharmaceutical use.
Current conversion strategies are often unable to fully
specify a defined cell fate. HpSCs have the potential to
provide an unlimited source for transplantable hepato-
cytes. However, it is still unclear whether HpSCs exist in
adult tissue [46]. In our study, we used FACS for cell sur-
face antigen screening, microarray, single cell tracing, col-
ony forming assays and siRNA transfection, BrdU-
labeling, and serial cell sorting to confirm the stem cell
characteristics of the CDCP1+CD90+CD66– subpopula-
tion in human primary FLCs. Our work revealed that hu-
man primary FLCs expressing CDCP1+CD90+CD66–
constituted a pool of HpSCs with self-renewal, clonal ex-
pansion, and bipotential capability in vitro as well as in-
vivo engraftment that could fully proliferate and mature
for months after transplantation in mouse liver.
Many surface markers have been reported to be useful
for human HpSC isolation. Schmelzer et al. [16] and
Tanaka et al. (2009) [47] reported that EpCAM+ cells
(See figure on previous page.)
Fig. 3 Bipotential differentiation capabilities of single HpSC-derived clones. a qPCR analysis of hepatocyte markers, cholangiocyte markers, and stem
cell-related markers. HpSC clones, FACS-sorted single HpSC-derived clones after culture for 14 days; hFetal liver, samples from human primary FLCs;
hAdult liver, samples from human adult liver cells. Results shown as mean ± SD (n = 3 independent experiments). Mann–Whitney test, *P < 0.05,
**P < 0.001, NS no significant difference. b Immunocytochemical staining of hepatocyte markers of ALB and AFP and cholangiocyte-specific markers
CK7 and CK19 in single human HpSC-derived colonies after culture for 40 days. Nuclei counterstained with DAPI. Scale bars: 100 μm. c Hepatocyte
differentiation capability of single HpSC-derived colonies characterized after long-term culture for up to day 90 in vitro by Periodic acid–Schiff (PAS)
staining and by positive immunocytochemical staining with human ALB, human CYP3A4, human CYP2D6, and human CYP1A2. Nuclei counterstained
with DAPI. Scale bars: 100 μm. d Cholangiocytic cyst formation of single HpSC-derived colonies. FACS-sorted single HpSC-derived colonies were
replated in an extracellular matrix gel, and several epithelial cysts were formed after culture for 14 days. CK7 was positively detected in cysts. Cells
stained with antibodies against ALB and CK7. Nuclei counterstained with DAPI. Scale bars: 50 μm. Experiments were performed at least three times,
representative data are shown. HpSC hepatic stem cell, ALB Albumin, CK cytokeratin
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have stem cell self-renewal and colony-forming capabil-
ity compared with EpCAM– cells in the ductal plates in
fetal liver. Our HpSCs isolated from human fetuses at
14–18 weeks of gestation showed a low EpCAM fre-
quency. These results are similar to a report by Schmel-
zer et al. [16], who found that only 5% of EpCAM+ cells
in human fetuses of 16–20 weeks gestational age were
HpSCs, whereas about 95% of the EpCAM+ cells were
hepatoblasts, indicating that hepatoblasts positively ex-
press EpCAM and that EpCAM alone is not sufficient
for HpSC isolation [20, 48]. Moreover, Yanai et al. (2010)
[49] found that DLK was first expressed in livers from
22-week-old fetuses and was downregulated in livers
from 38-week-old fetuses, indicating that DLK is not a
broad HpSC marker throughout the development
process. In our study, besides CD90, we report the first
use of CDCP1 as a marker for human HpSC isolation.
We detected that the expression of the CDCP1 gene in
human HpSC was about 37-fold higher than that in hu-
man adult livers; moreover, our previous data demon-
strated that there was a difference in CDCP1 expression
during different stages of development. Indeed, CDCP1
expression in human iPS-derived liver buds was over
200-fold higher than that in human iPS cells [50], imply-
ing the specificity and origin of CDCP1 in human HpSC
identification. In addition, freshly sorted CDCP1+CD90
+CD66 HpSCs and single CDCP1+CD90+CD66– HpSC-
derived clones on culture day 14 were negative for AFP
expression, but could be matured into AFP-positive he-
patocytes on culture day 40, indicating that the main dif-
ference between CDCP1+CD90+CD66– HpSCs and
hepatoblasts is expression of AFP [51]. Previous reports
showed that AFP-negative HpSCs were the precursors of
hepatoblasts [51], implying that CDCP1+CD90+CD66–
HpSCs might represent the precursors of hepatoblasts.
Furthermore, sorted CDCP1+CD90+CD66– HpSCs
maintained stable rates of CDCP1+CD90+ cells after up
to four serial sortings, indicating that their self-renewal
capabilities could be maintained in vitro. Single CDCP1
+CD90+CD66– HpSCs could give rise to cells containing
both hepatocyte and cholangiocyte characteristics veri-
fied by positive staining with HpSC markers (ALB, AFP,
CK7, and CK19), and long-term culture yielded HpSCs
with mature hepatocyte functions, including glycogen
storage and hepatocyte metabolism-related protein in-
duction. To our knowledge, this is the first report de-
scribing the isolation of self-renewing and bipotent
human HpSCs using CDCP1.
To study whether CDCP1+CD90+CD66– HpSCs may be
applicable in cell-based therapies, we examined the in-vivo
engraftment capacity of CDCP1+CD90+CD66– HpSCs.
Thirty days after transplantation, human HpSC-derived
clonal clusters were detected easily in recipient livers. In
comparison with transplantation of human primary FLCs,
transplantation of human HpSCs yielded a higher repopula-
tion efficiency (over 90% on average) and exhibited pro-
longed longevity in recipient livers. Moreover, increased
levels of human ALB were detected in human HpSC-
repopulated livers, indicating that human HpSCs could be
fully matured into functional hepatocytes compared with
transplanted human FLCs. In addition, debrisoquine hy-
droxylation measurement in human HpSC-derived human-
ized livers also confirmed that human HpSC-repopulated
livers had normal drug metabolism capacity.
Conclusions
These data provide evidence that CDCP1 acts as a spe-
cific marker of human HpSCs and that application of
CDCP1 for identifying human HpSCs for isolation may
contribute to regenerative therapies of liver diseases and
to understanding the mechanism of organogenesis.
Methods
Animal model and human primary liver cells
Albumin promoter-driven uPA-transgenic mice produced
in severely immunodeficient NOG mice (referred to as
uPA-NOG mice) were supplied by Laboratory Animals
Research Department, Central Institute for Experimental
Animals (Kawasaki, Japan). Animals were maintained and
operated upon in accordance with protocols approved by
the Laboratory Animal Resource Center of Yokohama
City University (No. FA-14-075).
Human primary FLCs were obtained from Cell Sys-
tems (Cat No. CS-ABI-3716; Kirkland, WA, USA),
and were separated and pooled from five human fetus
between embryonic weeks 14 and 18 by the Applied
Cell Biology Research Institute (ACBRI) with donor
permission.
Table 1 Bipotential capability in single HpSC-derived colonies during serial sorting
Serial sorting Single ALB+ (%) Single CK7+ (%) Double negative (%) Double positive (%)
First 0.3 ± 0.9 18.6 ± 13.0 9.1 ± 4.7 72.0 ± 11.8
Second 0.1 ± 0.1 10.3 ± 6.6 8.1 ± 5.3 81.5 ± 9.8
Third 03 ± 0.6 2.7 ± 3.0 6.7 ± 4.0 90.3 ± 2.5
Fourth 0.0 12.9 ± 9.1 9.6 ± 7.4 77.5 ± 10.8
Immunostaining of human ALB and human CK7 in HpSC colonies derived from the first, second, third, and fourth sorting performed as described in Fig. 4c.
Numbers represent percentage of ALB and/or CK7 stained or not stained in each colony. Results shown as mean percentage ± SD (n = 3 independent experiments)
ALB Albumin, CK cytokeratin, HpSC hepatic stem cell
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Cell culture and BrdU labeling
We used a low-density clonogenic culture system for hu-
man primary FLCs as described previously [17], with
some modifications. Human primary FLCs and/or flow
cytometry-fractionated cells were plated in DMEM nu-
trient mixture F-12 Ham (DMEM/F12 1:1 mixture;
Sigma, St. Louis, MO, USA) supplemented with 10%
fetal bovine serum (FBS), human γ-insulin (1.0 μg/ml;
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also Additional file 4: Figure S4. CDCP1 CUB domain-containing protein 1
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Wako, Japan), nicotinamide (10 mM, Sigma), dexa-
methasone (100 nM, Sigma), and L-glutamine (2 mM,
Gibco BRL) in dishes coated with type IV collagen (Bec-
ton Dickinson Labware) for at least 2 weeks with
complete medium changes every 5 days. Growth factors
were added in the first 24-h culture of human recombin-
ant hepatocyte growth factor (HGF, 50 ng/ml; Sigma)
and epidermal growth factor (EGF, 10 ng/ml; Sigma).
For passaging, culture medium was removed, and cells
were treated with 0.05% trypsin–EDTA (Gibco) at room
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Fig. 6 Engraftment and repopulation of uPA-NOG mouse liver with human HpSCs. a Macrophotography of a humanized liver 1 month after being
transplanted with human HpSCs. b Human HpSC-derived liver structure in a humanized liver lobe (H&E). m mouse liver region, h human HpSC-derived
liver region. Scale bar: 50 μm. c, d Immunohistochemistry used to distinguish human liver cells from mouse liver cells with anti-human ALB (red) and
anti-human nuclear antigen (green). Nuclei stained with DAPI (blue). Scale bars: 50 μm (c) and 1000 μm (d). e Immunostaining of humanized liver with
human ALB (red) and human CK19 (green). Nuclei stained with DAPI (blue). Scale bar: 50 μm. Results representative of at least three independent
experiments. f Chimeric rate in uPA-NOG mice 1 month after donor cell transplantation. Data represent mean ± SEM (n = 8 independent experiments).
Mann–Whitney test, **P = 0.0042 between human primary FLCs and human HpSCs. g Human albumin detection in mouse sera 1 month after donor
cell transplantation. Data shown as mean ± SD (n= 5 independent experiments). Mann–Whitney test, P = 0.0079 between human primary FLCs and
human HpSCs. ND undetectable. h Kaplan–Meier survival curve of uPA-NOG mice after human primary FLC and HpSC transplantation (n= 7 in each group).
Log-rank (Mantel–Cox) test, P = 0.0001. i Pharmacokinetic analysis of serum metabolite 4-OH debrisoquine formation to debrisoquine in
sera of human HpSC-derived humanized mice and sham mice. Data shown as mean value ± SEM (n = 3 independent experiments).
Mann–Whitney test, P = 0.0159. See also Additional file 5: Figure S5. H&E hematoxylin and eosin, hALB human albumin, HpSC hepatic
stem cell, FLC primary fetal liver cell, Tx treatment, CK cytokeratin, 4-OH-DB/DB 4-hydroxy-debrisoquine to debrisoquine
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temperature for 5 min and then gently detached from
the dish. Suspended cells were neutralized and washed
with culture medium containing 10% FBS. The viability
of dissociated cells was never lower than 90% by trypan
blue exclusion detection. The plating cell density of cells
varied depending on the experimental design.
For 3D culture, 3D chips (gifts from Kurarey Co. Ltd,
Tsukuba, Japan) were precoated with mouse collagen
type IV (BD Biosciences, Bedford, MA, USA) according
to the manufacturer’s instructions. Cells were cultured
on 3D chips at a density of 7.5 × 104 cells/cm2.
BrdU-pulsed cells were collected after incubation with
BrdU at a final concentration of 10 μM in cell culture
medium. Multicolor immunofluorescent staining of cell
surface antigens was performed using a BrdU flow kit
(BD Pharmingen, San Jose, CA, USA) according to the
manufacturer’s instructions.
Antigenic profiling and sorting with flow cytometry
Suspended cells were incubated with fluorochrome-
conjugated monoclonal antibodies (mAbs) on ice for
30 min in the dark. PBS with 2% FBS was used as a washing
solution and antibody diluant. A two-step incubation was
performed with biotinylated primary antibodies and a
streptavidin-labeled fluorochrome reaction. All labeled
mAbs and labeled fluorochromes were purchased from
Becton Dickinson unless otherwise indicated. The following
mAbs and fluorochromes were used as primary antibodies:
fluorescein isothiocyanate (FITC)-conjugated anti-human
CD66 (hCD66FITC), hCD13FITC, hCD24FITC,
hCD29FITC, and hEpCAMFITC (Miltenyi Biotec); allophy-
cocyanin (APC)-conjugated hCD45 (hCD45APC),
hCD90APC, hCD81APC, hCD117APC, hLGR5APC (Mil-
tenyi Biotec), and hCD133/2APC (Miltenyi Biotec); phyco-
erythrin (PE)-conjugated hCDCP1 (hCDCP1PE), hCD34PE,
hCD44PE, hCD49fPE, hCD140aPE, hCD166PE, and
hCD138PE (Miltenyi Biotec); biotinylated hCD54
(hCD54Bio; eBioscience), hCD55Bio, and hCD56Bio; hDLK
(IgG1, Abcam); and rabbit anti-LDLR (Abcam). Secondary
antibodies were as follows: streptavidin-labeled APC, goat
anti-mouse IgG1-APC, and goat anti-rabbit IgG-Alexa 488
(Invitrogen, Carlsbad, CA, USA). Cell profiling analyses and
sorting were performed on a high-speed cell sorter, MoFlo
(DakoCytomation).
Statistics
The statistical significance of differences was evalu-
ated by the Mann–Whitney U test when two groups
were compared or by one-way analysis of variance
(ANOVA) and Bonferroni’s multiple comparison test
when multiple groups were compared. We used the
log-rank (Mantel–Cox) test and Kaplan–Meier
method to assess post-transplantation survival. P <
0.05 was considered statistically significant, Statistical
analysis was performed using Graphpad Prism.
Additional experimental procedures are listed in
Additional file 6.
Accession numbers
The microarray data utilized in this study were deposited
under the GEO accession numbers GSE62933 and GSE
62998 for Additional file 3: Figure S3.
Additional files
Additional file 1: Figure S1. Showing stem cell characteristics of
human primary FLCs, related to Fig. 1. A. Representative images of
human primary FLCs under low-density culture from 100–500 cells/cm2.
Clonogenicity was observed at a density lower than 200 cells/cm2. The
white-boxed image is a magnified image. Numbers represent the plating
cell density. Scale bars: 200 μm. B. Immunofluorescence labeling of hu-
man primary FLCs with human CK19 (green, left), human AFP (red, left),
human CK19 (green, right), and human ALB (red, right). The lower lane
shows a magnified image of the upper lane. Nuclei were counterstained
with DAPI. Scale bars: 50 μm. C. Flow cytometry was used to analyze the
CD49f+/lowCD29+ hepatic stem cell fraction between mouse primary
FLCs and human primary FLCs. The framed subpopulation shows the
previously reported CD49f+/lowCD29+ hepatic stem cell population in
mouse primary FLCs and human primary FLCs. D. Representative FACS
histogram plots of human primary FLCs for stem cell-related markers.
Percentages indicate positive cells that express each respective marker, with
unstained control cells (filled histogram) and cells stained with antibodies
against the surface proteins (empty histogram). (PDF 725 kb)
Additional file 2: Figure S2. Showing characteristics of putative CDCP1
+CD90+CD66– HpSCs, related to Fig. 1. Immunophenotype of HpSCs after
7 days in culture. Representative flow cytometry histograms of stem cell-related
surface markers CD24, CD49f, CD44, CD55, CD166, CD54, CD117, CD138,
CD140a, EpCAM, CD34, DLK, and CD13, and the hepatic C virus receptors
CD81 and LDLR. Percentages indicate positive cells that express each respective
marker, with unstained control cells (filled histogram) and cells stained with
antibodies against the surface proteins (empty histogram). (PDF 78 kb)
Additional file 3: Figure S3. Showing microarray analysis and
identification of CDCP1+CD90+CD66– HpSCs, related to Fig. 1. Heatmap view of
(A) the Wnt signaling pathway (GO:0016055) (raw signal > 1000), (B) plasma
membrane part (GO:0044459) (more than 3-fold changes in both AH vs HpSCs
and FLCs vs HpSCs), and (C) stemness and other related genes. HpSCs-1 and
HpSCs-2 represent FACS-sorted fresh CDCP1+CD90+CD66– HpSCs; FLCs
represent samples from human primary FLCs; AH-1 and AH-2 represent
samples from human adult liver cells. (PDF 203 kb)
Additional file 4: Figure S4. Showing CDCP1 knockdown blocks HpSC
migration, related to Fig. 5. A Migration of HpSCs was evaluated using
transwell chambers. HpSCs transfected with CDCP1 siRNA, negative control
siRNA, or untreated HpSCs were plated 24 h after transfection on 24-well
transwell plates. Cells that migrated through the pores to the under surface
of the membrane were counted. Lower lane shows a magnified image of
the upper lane. Scale bars: 100 μm. B Quantification of the migrated cell
numbers. Con, untransfected HpSCs; siNC, HpSCs transfected with negative
control siRNA; siCDCP1, HpSCs transfected with siCDCP1. Results shown as
mean ± SD (n = 3 independent experiments). Mann–Whitney test, *P < 0.05,
NS no significant difference. (PDF 292 kb)
Additional file 5: Figure S5. Showing assessment of in-vivo engrafted
human HpSCs in uPA-NOG mice, related to Fig. 6. A Representative
karyotyping image of expanded HpSC cultured for 50 days (P8), illustrating a
normal chromosomal count (n= 46). B Image of a macroscopic whole mouse
liver 1 month after transplantation of human BMI1-overexpressing HpSCs.
GFP fluorescence shows human EGFP-HpSCs. C Flow cytometric analysis of
mice liver engrafted with human HpSCs. Cells were analyzed with
human HLA-ABC and mouse H2Kd expression in dissociated humanized
livers of 1 month. HLA antibody does not cross-react with mouse cells
(n = 3 independent experiments). (PDF 134 kb)
Zhang et al. Stem Cell Research & Therapy  (2018) 9:29 Page 12 of 14
Additional file 6: Contains supplementary material and methods,
including RNA interference, induction of cholangiocytic cyst formation by
HpSCs, retroviral vector construction and transduction, histochemistry
and immunohistochemistry, real-time PCR (qPCR), hepatic function assays,
cell transplantation, microarray, flow cytometric analysis of transplanted
liver cells obtained by collagenase perfusion, human ALB detection, and
drug metabolite detection. (PDF 366 kb)
Abbreviations
AAT: Alpha-1 antitrypsin; AFP: Alpha-fetoprotein; ALB: Albumin; BrdU: 5-
Bromo-2-deoxyuridine; CDCP1: CUB domain-containing protein 1; CFU-
C: Colony-forming unit cell; CK19: Cytokeratin 19; CK7: Cytokeratin 7;
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